China VenturesChina Ventures 中华创投协会DEAL MARKETPLACE
IPO

11 Nov 2026China VenturesKirkland & ellis

Neautus raises HK$262m in Hong Kong IPO, 2,190 times oversubscribed

Sichuan Neautus raised about HK$262m on the Hong Kong Main Board, with its public offer tranche 2,190.99 times covered and shares priced at HK$40.20 each.

Neautus raises HK$262m in Hong Kong IPO, 2,190 times oversubscribed
Image: China Ventures

What happened

Sichuan Neautus Traditional Chinese Medicine listed on the Hong Kong Main Board on 11 November, raising about HK$262m from 6,517,300 H shares at HK$40.20 each. The public offering tranche was 2,190.99 times oversubscribed. GF Capital (Hong Kong) and ABCI Capital were joint sponsors.

The numbers

ItemFigure
Gross proceedsAbout HK$262m
Shares offered6,517,300 H shares
Offer priceHK$40.20
Public tranche2,190.99 times covered
Revenue rank in decoction-ready TCM, 2025Second in China
MarketsHong Kong, Taiwan, Vietnam, Malaysia

Why it matters

Neautus makes decoction-ready TCM, the step between raw herbs and hospital dispensing. It is a scaled supplier with real revenue, and its distribution into Hong Kong, Taiwan, Vietnam and Malaysia gives it an export angle that most domestic TCM suppliers lack.

The counter-argument is that a 2,190-times retail book reflects a small float and hot money rather than institutional conviction, and TCM quality standards remain a regulatory risk. Even so, the listing shows Hong Kong will fund consumer-health stories with revenue, not only technology.

What to watch

  • Post-debut price once the retail book clears.
  • Use of proceeds for capacity expansion.
  • Growth of Southeast Asian distribution into a material export business.

Original source: Kirkland & Ellis · 11 Nov 2026

All insights ↗